Hawkhill Therapeutics

Hawkhill Therapeutics is a pre-clinical biotechnology company developing oral, muscle-sparing therapeutics for obesity and metabolic health.

Its programme targets a clinically validated mechanism to achieve fat-selective weight loss while preserving muscle mass, addressing a recognised limitation of current GLP-1 receptor agonist drugs.

Operating as a lean virtual biotech, the company outsources chemistry and biology to contract research organisations with the aim of delivering a clinic-ready candidate efficiently.